Shaping the future

of precision
medicine.

FogPharma is pioneering a
new class of drugs to
address the limitations of
today’s precision medicines
and achieve universal
druggability.

Helicon Polypeptide
Therapeutics

We’ve learned from nature that α-helices in

proteins are critically important for mediating
their interactions with other proteins, and can
also endow proteins with unique features, like
the ability to embed themselves in cellular
membranes.

At FogPharma, we’ve developed Helicon™

polypeptides based on this privileged α-helix and
used our innovative discovery engine to discover
novel therapeutics against some of the most
relevant and historically difficult-to-target
disease proteins.

Helicon polypeptides are designed to combine

the cell-permeability and oral dosing optionality
of traditional small molecule drugs with the high
specificity, broad target accessibility and rapid
discovery arc of monoclonal antibody drugs.

Our technology is centered on

constraining short chains of amino
acids — polypeptides — in a
specific folded shape known as an
α-helical conformation, which
confers upon them unique drug-like
properties. The α-helical fold
intrinsically cloaks the polarity of
the peptide backbone, allowing
sufficiently hydrophobic peptides
to cross membranes and enter
cells.

This combination of cell penetration,

drug-like properties and broad
targeting ability make Helicon
polypeptides uniquely suited to solving
the limitations of today’s precision
medicines.

See Publications

Democratizing
Drug Discovery

FogPharma’s approach aims not only to discover

novel polypeptide therapeutics against the most
elusive disease targets, but also to dramatically
accelerate the speed and scalability of drug
discovery compared to many of today’s standard
processes.

Our multiplexed, tandem discovery engines

integrate cutting-edge technologies such as
directed evolution, proprietary α-helix
conformational hyperstabilization chemistry,
highly multiplexed drug optimization technology,
analytical and predictive data science including
machine learning and deep learning, structure-
based drug discovery and multiscale
manufacturing.

Using our tandem discovery engines,

FogPharma’s scientists are able to design,
synthesize and evaluate thousands of new
Helicons each week in both biochemical and cell-
based assays, progressing early hits into leads in
a matter of months.

Our aspiration is to push our multiplexing

technology to its limits, and build the world’s
fastest and most powerful drug discovery engine
– one which can be deployed to address the
needs of human medicine at an unprecedented
scale.

Hit Discovery

Hit-to-Lead

Lead Optimization

Helicon Phage Screening

Multiplexed Synthetic Library

Screening

Our pipeline programs are

designed to make a significant
impact for patients.

With our tandem drug discovery engines, we are

building a robust pipeline of Helicon polypeptide
therapeutics, with our lead programs targeting
the most elusive drivers of cancer.

View Our Pipeline

Contact Us

Privacy Policy

Terms & Conditions

2022© FogPharma